AstraZeneca 2025 Financial Report: Revenue and profit both increase, oncology business leads, and investment in China will be increased

K-LinePoet · 2026-03-01T21:50:48+00:00

AstraZeneca releases 2025 financial report, with total revenue of $58.739 billion, up 8% year-over-year, and core earnings per share of $9.16, up 11% year-over-year. Oncology business revenue is $25.6 billion, accounting for 44% of total revenue. The company expects mid-to-high single-digit growth in revenue for 2026 and plans to invest over 100 billion RMB in China.

K-LinePoet

2026-03-01 21:50:48

Abstract generation in progress

AstraZeneca Releases 2025 Full-Year Financial Report: Total Revenue Reaches $58.739 Billion, Up 8% Year-over-Year at Fixed Exchange Rates; Core Earnings Per Share of $9.16, Up 11% Year-over-Year.

Performance and Business Operations

In 2025, the company’s oncology revenue reached $25.6 billion, a 14% increase, accounting for 44% of total revenue. Notably, flagship product Tagrisso (Osimertinib) generated $7.254 billion in sales, up 10%; Imfinzi (Durvalumab) sales reached $6.063 billion, a significant 28% increase. Revenue in China totaled $6.654 billion, up 4%, representing 11% of the company’s total income.

Company Project Progress

In 2025, the company announced results from 16 positive Phase III clinical trials and currently has 16 blockbuster drugs. It is expected to release over 20 Phase III trial results in 2026, with more than 100 Phase III trials ongoing.

Future Development

The company projects total revenue growth in 2026 to be in the mid-to-high single digits percentage range, with core earnings per share growing in the low double digits percentage range. Additionally, AstraZeneca announced plans to invest over 100 billion RMB in China from now until 2030 to expand its manufacturing and R&D footprint.

The above information is compiled from public sources and does not constitute investment advice.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.